Life sciences & health care predictions | Deloitte US has been added to your bookmarks.
Life sciences and health care predictions 2022
The future awakens
The year is 2022. The quantified self is alive and well, digital technologies have transformed the culture of health care and new entrants have disrupted delivery models. This report from Deloitte UK's Centre for Health Solutions offers some predictions that, if they come true, will shake up the life sciences and health care industry in the next five years.
- What will life sciences and health care look like in 2022?
- Download the full report
- The six predictions for 2022
- Get in touch
- Related topics
This Deloitte Centre for Health Solutions’ report builds on its 2014 report Life sciences and
This new report evaluates evidence in 2017 and provides six new predictions of what the life sciences and
Challenging times lie ahead arising from a growing and aging population and a tidal wave of chronic diseases. This report presents an optimistic view of the future, calling businesses to awaken to the possibilities that lie ahead.
The six predictions for 2022
The key enablers to thrive and survive the future
- Wide-scale adoption of new digital and cognitive health technologies
The life sciences and
health careindustries have traditionally been slow to use data and analytics due to multiple disconnected systems, poor data quality and patient and provider behaviors that have been difficult to change. However, we are now at a tipping point in advanced technology adoption towards an outcomes-based, patient-centric care model.
- Recruitment and retention of new skills and talent
The delivery of efficient and effective services requires organizations to have access to appropriate specialist and generalist skills and talent, including digital and analytical skills. How the
health careindustry responds in relation to recruitment and retention of the right talent and skills will determine how well these predictions are realized.
- A new approach to regulation
For the past decade, most life sciences and
health carecompanies have highlighted that a risk-averse approach to regulation has impeded adoption of innovation. The evidence today and predictions for tomorrow illustrate that this is changing.